These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 20403386

  • 1. Differential inhibition of lamivudine-resistant hepatitis B virus by allele-specific RNAi.
    Teng X, Xu WZ, Hao ML, Fang Y, Zhao YX, Chen SJ, Li D, Gu HX.
    J Virol Methods; 2010 Sep; 168(1-2):6-12. PubMed ID: 20403386
    [Abstract] [Full Text] [Related]

  • 2. Application of allele-specific RNAi in hepatitis B virus lamivudine resistance.
    Teng X, Liu JY, Li D, Fang Y, Wang XY, Ma YX, Chen SJ, Zhao YX, Xu WZ, Gu HX.
    J Viral Hepat; 2011 Oct; 18(10):e491-8. PubMed ID: 21914068
    [Abstract] [Full Text] [Related]

  • 3. The short hairpin RNA driven by polymerase II suppresses both wild-type and lamivudine-resistant hepatitis B virus strains.
    Ren GL, Fang Y, Ma HH, Lei YF, Wang D, Xu MC, Wang PZ, Huang CX, Nie OH, Sun YT, Bai XF.
    Antivir Ther; 2007 Oct; 12(6):865-76. PubMed ID: 17926641
    [Abstract] [Full Text] [Related]

  • 4. Combination therapy of siRNAs mediates greater suppression on hepatitis B virus cccDNA in HepG2.2.15 cell.
    Xin XM, Li GQ, Guan XR, Li D, Xu WZ, Jin YY, Gu HX.
    Hepatogastroenterology; 2008 Oct; 55(88):2178-83. PubMed ID: 19260501
    [Abstract] [Full Text] [Related]

  • 5. Construction and expression of eukaryotic plasmids containing lamivudine-resistant or wild-type strains of Hepatitis B Virus genotype C.
    Xu WZ, Fang Y, Li D, Wang Y, Shang QL, Li GQ, Teng X, Gu HX.
    World J Gastroenterol; 2008 Jun 21; 14(23):3733-8. PubMed ID: 18595141
    [Abstract] [Full Text] [Related]

  • 6. RNA interference inhibits hepatitis B virus gene expression and replication in HepG2-N10 cells.
    Ren JL, Pan JS, Cheng T, Dong J, Lu YP, Huang SJ, Shi HX, Wang L, Lian YM.
    Chin J Dig Dis; 2006 Jun 21; 7(4):230-6. PubMed ID: 17054586
    [Abstract] [Full Text] [Related]

  • 7. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
    Ohkawa K, Takehara T, Kato M, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N.
    J Infect Dis; 2008 Oct 15; 198(8):1150-8. PubMed ID: 18713056
    [Abstract] [Full Text] [Related]

  • 8. Effect of various pyrimidines possessing the 1-[(2-hydroxy-1-(hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2'-deoxyribose, on wild-type and mutant hepatitis B virus replication.
    Kumar R, Semaine W, Johar M, Tyrrell DL, Agrawal B.
    J Med Chem; 2006 Jun 15; 49(12):3693-700. PubMed ID: 16759112
    [Abstract] [Full Text] [Related]

  • 9. In vitro resistance to interferon-alpha of hepatitis B virus with basic core promoter double mutation.
    Wang Y, Wei L, Jiang D, Cong X, Fei R, Chen H, Xiao J, Wang Y.
    Antiviral Res; 2007 Aug 15; 75(2):139-45. PubMed ID: 17397939
    [Abstract] [Full Text] [Related]

  • 10. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
    van der Eijk AA, Hansen BE, Niesters HG, Janssen HL, van de Ende M, Schalm SW, de Man RA.
    J Viral Hepat; 2005 Jul 15; 12(4):364-72. PubMed ID: 15985006
    [Abstract] [Full Text] [Related]

  • 11. [Construction of whole-genome lamivudine-resistant hepatitis B virus mutant and its replication and expression in HepG2 cells].
    Sun J, Wang C, Wen SJ, Wang ZH, Hou JL.
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jul 15; 27(7):991-3. PubMed ID: 17666334
    [Abstract] [Full Text] [Related]

  • 12. Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication.
    Yang J, Bo XC, Ding XR, Dai JM, Zhang ML, Wang XH, Wang SQ.
    J Viral Hepat; 2006 Mar 15; 13(3):158-65. PubMed ID: 16475991
    [Abstract] [Full Text] [Related]

  • 13. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro.
    Vincent IE, Lucifora J, Durantel D, Hantz O, Chemin I, Zoulim F, Trepo C.
    Antivir Ther; 2009 Mar 15; 14(1):131-5. PubMed ID: 19320247
    [Abstract] [Full Text] [Related]

  • 14. Evolution of hepatitis B virus precore/basal core promoter gene in HBeAg-positive chronic hepatitis B patients receiving lamivudine therapy.
    Lin CL, Liao LY, Wang CS, Chen PJ, Lai MY, Chen DS, Kao JH.
    Liver Int; 2004 Feb 15; 24(1):9-15. PubMed ID: 15101995
    [Abstract] [Full Text] [Related]

  • 15. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
    Wakil SM, Kazim SN, Khan LA, Raisuddin S, Parvez MK, Guptan RC, Thakur V, Hasnain SE, Sarin SK.
    J Med Virol; 2002 Nov 15; 68(3):311-8. PubMed ID: 12226816
    [Abstract] [Full Text] [Related]

  • 16. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F, Akuta N, Suzuki Y, Sezaki H, Arase Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Satoh J, Watahiki S, Kumada H.
    J Med Virol; 2006 Mar 15; 78(3):341-52. PubMed ID: 16419116
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of novel strategies to combat hepatitis B virus targetting wild-type and drug-resistant mutants in experimental models.
    Zoulim F.
    Antivir Chem Chemother; 2001 Mar 15; 12 Suppl 1():131-42. PubMed ID: 11594680
    [Abstract] [Full Text] [Related]

  • 18. The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.
    Billioud G, Pichoud C, Puerstinger G, Neyts J, Zoulim F.
    Antiviral Res; 2011 Nov 15; 92(2):271-6. PubMed ID: 21871497
    [Abstract] [Full Text] [Related]

  • 19. Whole genome expression profiling of hepatitis B virus-transfected cell line reveals the potential targets of anti-HBV drugs.
    Ding XR, Yang J, Sun DC, Lou SK, Wang SQ.
    Pharmacogenomics J; 2008 Feb 15; 8(1):61-70. PubMed ID: 17505500
    [Abstract] [Full Text] [Related]

  • 20. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.
    Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, Miyano Y, Koike H, Kobayashi M, Koida I, Arase Y, Saitoh S, Murashima N, Ikeda K, Kumada H.
    Hepatology; 1998 Jun 15; 27(6):1711-6. PubMed ID: 9620347
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.